Evaxion A (EVAX) Cash from Investing Activities (2020 - 2022)
Evaxion A's (EVAX) quarterly Cash from Investing Activities came in at -$77000.0 in Q2 2022, up 90.63% YoY from -$40391.8 in Q2 2021, and up 51.57% on a QoQ basis from -$159000.0 in Q1 2022.
Evaxion A (EVAX) Cash from Investing Activities (2020 - 2022) Analysis & Trends
Evaxion A (EVAX) has 3 years of Cash from Investing Activities data on file, last reported at -$77000.0 in Q2 2022.
- Quarterly Cash from Investing Activities rose 90.63% year-over-year to -$77000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was -$2.2 million (down 57.25% YoY) and the FY2025 annual result came in at -$14000.0, down 366.67% from the prior year.
- Cash from Investing Activities rose to -$77000.0 in Q2 2022, from -$159000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$77000.0 in Q2 2022 to a low of -$1.2 million in Q3 2021.
- A 3-year average of -$359500.0 and a median of -$145000.0 in 2020 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities slumped 780.15% — and 2022, when it surged 90.63%.
- Tracing EVAX's Cash from Investing Activities over 3 years: stood at -$131000.0 in 2020, then tumbled by 780.15% to -$1.2 million in 2021, then jumped by 93.32% to -$77000.0 in 2022.
- The last three Cash from Investing Activities figures came in at -$77000.0 (Q2 2022), -$159000.0 (Q1 2022), and -$1.2 million (Q3 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -77,000.00 |
| Jun 30, 2022 | -77,000.00 |
| Mar 31, 2022 | -159,000.00 |
| Mar 31, 2022 | -159,000.00 |
| Sep 30, 2021 | -1.15 Mn |
| Sep 30, 2021 | -1.15 Mn |
| Jun 30, 2021 | -822,000.00 |
| Jun 30, 2021 | -822,000.00 |
| Mar 31, 2021 | -327,000.00 |
| Mar 31, 2021 | -327,000.00 |
| Sep 30, 2020 | -131,000.00 |
| Sep 30, 2020 | -131,000.00 |
| Jun 30, 2020 | -126,000.00 |
| Jun 30, 2020 | -126,000.00 |
| Mar 31, 2020 | -81,000.00 |
| Mar 31, 2020 | -81,000.00 |